Cover Image

Protective effect of rectal ozone therapy against oxidative stress in immunoglobulin A deficiency.


Abstract


The excess in the production of free radicals produces an imbalance between the prooxidants and antioxidants in favor of the former; which causes loss of redox control signaling and damage to biomolecules such as proteins, lipids and deoxyribonucleic acid. When homeostasis is altered in the redox metabolism of cells that participate in the immune response, they usually evolve into a situation of oxidative stress that facilitates cell dysfunction and death. The objective of our work was to study the effect of ozone on the regulation of redox status, necessary to maintain normal immune function in patients with immunoglobulin A deficiency. Patients and methods: The Research Ethics Committee conducted and approved a clinical trial and whose patients gave informed consent for inclusion. Sixty patients were randomly assigned to two groups: one receiving ozone rectal insufflation (study group-SG) and the second using Hebertrans® (control-GC group), subcutaneously. Pro-oxidant parameters (malondialdehyde-MDA and advanced oxidation protein products-AOPP) and antioxidant parameters (superoxide dismutase1-SOD1, catalase-CAT, glutathione peroxidase-GPx and total antioxidant capacity of serum) were measured. They were measured at the beginning and one month after treatment. Results: In the SG the MDA and the APOP of patients ?15 years, decreased significantly (p = 0.000) with respect to the control group. SOD1 in the SG increased in patients ?15 years (p = 0.006) and from 16 to 30 years of age (p = 0.040) with respect to GC. CAT in patients ?15 years of the SG increased significantly (p=0.001) with respect to initial values. The final result of the total antioxidant capacity in the SG was significantly (p=0.000) higher in patients ? 15 years, similar results were obtained in GPx (p=0.013). Conclusions: With ozone therapy, beneficial effects on the oxidation reduction balance were achieved. Medical ozone therapy may be an additional treatment option, for immunoglobulin A deficient patients with oxidative stress.

Keywords


ozone therapy; prooxidants; antioxidants; oxidative stress; redox; IgA deficiency

Full Text:

PDF

References


  1. Tristram G, Daniel P, Abba I, John B. Basic and Clinical Immunology. 10th. ed. Mexico.D.F:The Modern Manual;2002.

  2. Romero Á, Amores L. Inflammatory oxidative aging: a new theory with practical implications. Medisur. 2016;14(5).

  3. Reuter S, Gupta S, Chaturredi M, Aggarwal B. Oxidative stress, inflamat and cancer: how are they mixed? Free Radic Biol Med. 2010 Dec 4;9(11):1603-1616.

  4. Maciejczyk M, Mikoluc B, Pietrucha B, Heropolitanska E, Pac M, Motkowski R, et al. Oxidative stress mitochondrial abnormalities and antioxidant defense in Ataxia-Telangiectasia, Bloom Syndrome and Nijmegen breakage syndrome. Redox Biol. 2017 Apr;11:375-383.

  5. Pomier O, Gil L, Rodríguez F, Huetes L, González A, Bermúdez Y, et al. Indicators of oxidative stress in patients affected by HIV / AIDS with rheumatic manifestations. Rev Cubana Farm. 2012;46(3).

  6. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015 Nov;35(8):696-726.

  7. European Society for Immunodeficiencies [Internet]. Geneva: European Society for Immunodeficiencies; 2017. Registry. Diagnosis Criteria. New clinical diagnosis criteria for the ESID Registry; 2014 Mar. Available from: http://esid.org/Working-Parties/Registry/Diagnosis-criteria

  8. Pediatric Immunology Working Group. Management guidelines: general measures of infection prevention and chemoprophylaxis in primary immunodeficiencies. Arch Argent Pediatr. 2011;109(3):267–273.

  9. Formulario Nacional de Medicamentos. Intacglobin [National Drug Form. Intacglobin] [Internet]. Havana: Center for the Development of Pharmacoepidemiology; 2017 [cited 2019 Dec 28]. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=385. Spanish.

  10. Cruz MA, Rodríguez BN, Furones JA, Martín AD, Guerra LM, Páez AT. Prescription patterns of the transfer factor in 11 hospitals in Havana City. Cuban Rev. Public Health. 2005 Dec 31;(4):291–295.

  11. Méndez I, Menéndez S, Rivero J. Ozone therapy in AIDS. Cuban Rev Invest Biomed. 2005 Jan-Mar;24(1):69–71.

  12. León OS, Viebahn R, Cabreja GL, Espinosa IS, Matos YH, Roche LD, et al. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. Eur J Pharmacol. 2016 Oct;789:313–318.

  13. Díaz J, Padrón G, Menéndez S, Macias C. Immunomodulatory effect of ozone therapy in children with phagocyte-mediated immunity deficiency. Mediciego. 2012;18(1).

  14. Díaz J, Parés Y, Díaz A. The social and economic impact of ozone therapy on immunoglobulin deficiency A. Mediciego. 2014;20(suppl.1).

  15. Martínez G. World library on ozone therapy, a tool for research. Spanish magazine of ozone therapy. 2014;4(1):73-77.

  16. Viebahn R, León OS, Fahmy Z. Ozone in Medicine: The Low-Dose Ozone Concept — Guidelines and Treatment Strategies. Ozone Sci Eng OZONE-SCI ENG. 2012;34(6):408-424.

  17. Formulario Nacional de Medicamentos. Factor de transferencia [National Drug Form. Transfer factor] [Internet]. Havana: Center for the Development of Pharmacoepidemiology; 2017 [cited 2019 Dec 28]. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=380. Spanish.

  18. BIOPROCESS Online [Internet]. Pittsburg: BIOPREOCESS Online; 1996-2017. Product / Service Bioxytech LPO-586. Colorimetric assay for lipid peroxidation markers. Catalog No. 941012. OXIS International; 1997 [cited 2019 Dec 28]. Available from: https://www.bioprocessonline.com/doc/bioxytech-lpo-586-colorimetric-assay-for-lipi-0001

  19. Witko V, Friendlander M, Nguyen T, Capeillère C, Nguyen AT, Canteloup S. Advanced oxidation protein products as novel mediators of inflammation and monocytes activation in chronic renal failure. J Immunol. 1998 Sep 1;161(5):2524-2532.

  20. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974 Sep 16;47(3):469–474.

  21. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–126.

  22. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967 Jul;70(1):158–169.

  23. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Biochem anal. 1996 Jul 15;239(1):70–76.

  24. Martínez L, Mastandrea C, Benavente E, Roverano S, Paira S, Poletta G, et al. Evaluation of oxidative stress in patients with systemic lupus erythematosus and its possible relationship with environmental exposure to agrochemicals. Toxicol Act. Argent. 2016;24(1):10-20.

  25. Gutiérrez H, Patricia E. Oxidative stress and its impact on health. Research and Science. 2014;22(61):65-66.

  26. Sánchez V, Méndez N. Oxidative stress, antioxidants and disease. Rev Invest Med Sur Mex. 2013 Jul–Sep;20(3):161-168.

  27. Abbas AK, Lichtman AH. Cellular and molecular immunology. 8th. ed. Barcelona: Elsevier;2015.

  28. Coronado M, Vega S, Gutiérrez R, Vázquez M, Radilla C. Antioxidants: current perspective for human health. Rev Chil Nutr. 2015;42(2):206-211.

  29. Valacchi G, Bocci V. Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases? Curr Med Chem. 2013;20(27):3397-3415.

  30. Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol. 2003;31(3):398-404.

  31. Calunga JL, Trujillo Y, Menéndez S, Zamora Z, Alonso Y, Merino N, et al. Ozone oxidative post-conditioning in acute renal failure. Journal of Pharmacy and Pharmacology. 2009;61:1–7.

  32. Borrego A, Zamora ZB, González R, Romay C, Menéndez S, Hernández F, et al. Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats, Mediators Inflamm. 2004 Feb;13(1):13–19.

  33. Copello M, Menéndez S, Hernández F. Ozone therapy in retinitis pigmentosa patients: clinical evolution and oxidative stress behavior in retinitis pigmentosa patients treated with ozone therapy over 20 years. Ozone Sci Eng. 2012;34:476-483.

  34. Martinez G, Re L. Rectal administration and its application in ozone therapy. Int J ozone therapy. 2012;11:41-49.

  35. Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. Redox Biol. 2017;11:613-619.

  36. Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. J Cell Biochem. 2015;3:1-6.

  37. Sagai M, Bocci V. Mechanism of action involved in ozone therapy. Is healing induced via a mild oxidative stress? Med Gas Res. 2011;1:1-29.

  38. Re L, Martínez G, Bordicchia M, Malcangi G, Pocognoli A, Morales MA, et al. Is ozone pre-conditioning effect linked to Nrf2 / EpRE activation pathway in vivo? A preliminary result. Eur J Pharmacol. 2014;742:158-162.

  39. Galiè M, Costanzo M, Nodari A, Boschi F, Calderan L, Mannucci S, et al. Mild ozonisation activates antioxidant cell response by the Keap1 / Nrf2 dependent pathway. Free Radic Biol Med. 2018 Aug;20(124):114-121.

  40. Smith A, Oertle J, Warren D, Prato D. Ozone Therapy: A Critical Physiological and Diverse Clinical Evaluation with Regard to Immune Modulation, Anti-Infectious Properties, Anti-Cancer Potential, and Impact on Anti-Oxidant Enzymes. Open J Mol Integr Physiol. 2015;5:37-48.

  41. Carpendale MT, Freeberg J, Griffiss JM. Does ozone alleviate AIDS diarrhea? J Clin Gastroenterol. 1993;17(2).

  42. Baeza J, Cabo JR, Gómez M, et al. WFOTs review on evidence based ozone therapy. World Federation of Ozone Therapy. Brescia: WFOT; 2015.

  43. Hernández FA, Calunga JL, Turrent J, Menéndez S, Montenegro A. Ozone therapy effects on biomarkers and lung function in asthma. Arch Med Res. 2005;36:549-554.

  44. Padilla EM, Sueiro I, Quintero L, Domínguez C, Hernández AB, Ercia LE. Therapeutic uses of ozone in health services. Cuban Rev of Natural and Traditional Medicine. 2016;1(1).

  45. Bocci V, Zanardia L, Valacchi G, Borrelli E, Travagli V. Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases. Cardiovasc Hematol Disord Drug Targets. 2015;15(2):127-138.


Refbacks

  • There are currently no refbacks.